Combining an mTOR antagonist and receptor tyrosine kinase inhibitors for the treatment of prostate cancer.

Cancer Biology Program, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Institutes of Medicine, 300 Brookline Avenue, Boston, MA 02215, USA.
Cancer biology & therapy (Impact Factor: 3.63). 03/2007; 6(2):195-201. DOI: 10.4161/cbt.6.2.3588
Source: PubMed

ABSTRACT Inhibition of the mammalian target of rapamycin (mTOR) signaling pathway is a potentially useful therapeutic strategy in the treatment of advanced prostate cancer. However mTOR antagonists used as single agents are not likely to result in dramatic clinical responses, so that it is useful to identify prospective agents that might be useful in combination. We treated CWR22Rv1 and LNCaP prostate cancer cells with an mTOR inhibitor, rapamycin, alone, or in combination with either of two receptor protein kinase (RTK) inhibitors. We assessed the effects of these treatments on cell survival and activation of down-stream mTOR target proteins. Treatment with either PD16839, an EGFr antagonist, or imatinib mesylate (Gleevec), a PDGFr, c-kit and bcr/abl antagonist, enhanced the anti-proliferative effects of rapamycin. We therefore assessed the effects of treatment with the RTK antagonist alone and in combination with rapamycin on mTOR targeted proteins. RTK antagonists alone had no effect or paradoxically increased phosphorylation of the mTOR targeted proteins, p70 S6 kinase and ribosomal S6. In contrast, when these cells were treated with either RTK antagonist in the presence of rapamycin, there was a dramatic decrease in phosphorylation of these two mTOR-targeted proteins. These effects were not mediated through phospho-AKT. Since two separate RTK antagonists had additive antiproliferative effects in combination with an mTOR antagonist and were associated with a dramatic decrease in mTOR targeted proteins in cells with or without PTEN expression, the strategy deserves further evaluation for the treatment of prostate cancer.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Constitutive activation of PI(3)K–Akt–mTOR signaling is a frequently occurring event in human cancer and has also been detected in the majority of neuroendocrine tumors (NETs) of the gastroenteropancreatic system. Molecular analysis of NETs suggests, that in addition to mutations in certain tumor-suppressor genes (e.g., PTEN), multiple autocrine growth factor loops contribute to hyperactive PI(3)K–Akt–mTOR signaling, thus promoting unrestricted proliferation and resistance to apoptosis. These insights opened new perspectives for targeted therapy in NETs. In particular, several novel small-molecule inhibitors of tyrosine and serine/threonine kinases have demonstrated potent anti-tumor activity. This review will summarize current knowledge on PI(3)K–Akt–mTOR signaling, its role in proliferation and apoptosis, as well as novel therapeutic approaches targeting PI(3)K–Akt–mTOR pathway components in NET disease.
    Expert Review of Endocrinology &amp Metabolism 01/2008; 3(2):207-222.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Recent groundbreaking discoveries have revealed that IGF-1, Ras, MEK, AMPK, TSC1/2, FOXO, PI3K, mTOR, S6K, and NFκB are involved in the aging process. This is remarkable because the same signaling molecules, oncoproteins and tumor suppressors, are well-known targets for cancer therapy. Furthermore, anti-cancer drugs aimed at some of these targets have been already developed. This arsenal could be potentially employed for anti-aging interventions (given that similar signaling molecules are involved in both cancer and aging). In cancer, intrinsic and acquired resistance, tumor heterogeneity, adaptation, and genetic instability of cancer cells all hinder cancer-directed therapy. But for anti-aging applications, these hurdles are irrelevant. For example, since anti-aging interventions should be aimed at normal postmitotic cells, no selection for resistance is expected. At low doses, certain agents may decelerate aging and age-related diseases. Importantly, deceleration of aging can in turn postpone cancer, which is an age-related disease.
    Cancer biology & therapy 11/2013; 14(12). · 3.29 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: PTEN is one of the most commonly deleted/mutated tumor suppressor genes in human prostate cancer. As a lipid phosphatase and negative regulator of the PI3K/AKT/mTOR pathway, PTEN controls a number of cellular processes, includ-ing survival, growth, proliferation, metabolism, migration, and cellular architecture. Over the past 15 years since its discovery, a number of mechanisms governing PTEN expression and function, including transcriptional and post-transcriptional regulation, post-translational modifi cations, and protein–protein interactions, have been shown to be altered in human prostate cancer. The functions of PTEN within the cell have been expanded to include phosphatase-independent roles and functions within the nucleus. The generation of genetically engineered mouse models (GEMs) with deletion of Pten has further revealed that varying degrees of Pten loss in com-bination with other genetic alterations are able to recapitulate all spectrums of human prostate cancer, from tumor initiation to metastasis. With new methods of genomic and transcriptional analysis of human prostate cancer specimens, PTEN loss can potentially be used as a diagnostic and prognostic biomarker for prostate cancer, as well as predict patient responses to emerging PI3K/AKT/mTOR inhibi-tors. Finally, deeper insight into communication between the PI3K/AKT/mTOR and Ras/MAPK signaling pathways has led to the creation of metastatic murine prostate cancer models that develop lethal metastases, while new understanding of a feedback loop between PTEN and androgen receptor (AR) controlled pathways has unveiled a new mechanism for the development of castration-resistant prostate cancer (CRPC). Our expanded knowledge of PTEN and its role in prostate cancer 88 initiation and progression will inform the rational design of novel therapeutics that target PTEN-controlled pathways alone or in combination with other related path-ways for the treatment of metastatic and castration-resistant prostate cancer.
    Prostate Cancer: Biochemistry, Molecular Biology and Genetics, Protein Reviews 16, 16 edited by D.J. Tindall, 01/2013: chapter Pten in Prostate Cancer: pages 87-137; Springer., ISBN: 978-1-4614-6827-1

Full-text (2 Sources)

Available from
Dec 1, 2014